KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M

KalVista Pharmaceuticals, Inc.

NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.
FY2024 net loss $126.6M ($3.44/share) vs $92.9M ($3.33) prior year; no revenue.
Cash, cash equivalents and marketable securities $210.4M, up from $149.4M; raised $150.1M net in Feb 2024 offering.
R&D expenses $86.2M (prior $80.3M); G&A $54.3M (prior $30.6M) driven by commercial planning and employee costs.
Promoted Benjamin Palleiko to CEO in March 2024; strategic review of preclinical Factor XIIa program ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.